Preclinical Ischemic Stroke Multicenter Trials (PRISM) Collective Statement: Opportunities, Challenges, and Recommendations for a New Era
Stroke · 2026-01 · 57 (1)
DOI: 10.1161/strokeaha.125.052056 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stroke, 2026-01. Verfasst von Cenk Ayata und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Boston (C.A.). Hauptthemen laut MEDLINE: Ischemic Stroke, Randomized Controlled Trials as Topic, Multicenter Studies as Topic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 205 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NCI NIH HHS, NIA NIH HHS.
Themen: Schlaganfall
Abstract (Originalsprache)
Preclinical stroke research faces a critical translational gap, with animal studies failing to reliably predict clinical efficacy. To address this, the field is moving toward rigorous, multicenter preclinical randomized controlled trials (mpRCTs) that mimic phase 3 clinical trials in several key components. This collective statement, derived from experts involved in mpRCTs, outlines considerations for designing and executing such trials. mpRCTs offer advantages such as increased sample sizes, robust statistical design, incorporation of heterogeneity, and standardized protocols, but they face challenges in finding the right balance between standardization and heterogeneity, appropriate stroke model selection, and outcome measures, as well as the implementation of complex network infrastructure. We discuss the importance of rigorous study design, including appropriate stroke models, representation of biological variables and comorbidities, functional outcome readouts, and handling of attrition and mortality. Statistical considerations such as adaptive sequential designs, covariate adjustments, and appropriate handling of missing data are also addressed. The integration of machine learning, the implementation of common data elements, and the selection of appropriate therapeutic candidates are crucial for maximizing the efficiency and utility of mpRCTs. Furthermore, the transition toward mpRCT platforms, akin to clinical trial platforms, holds promise for facilitating continuous evaluation of therapies. Finally, we discuss data-sharing practices and the collateral benefits of mpRCTs, emphasizing their potential to improve preclinical stroke research and bridge the translational gap. Altogether, we hope that this article will serve as a starting point for a lasting debate on the future of stroke mpRCTs and their evolution toward a universally accepted set of principles.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Massachusetts General Hospital, Boston (C.A.).
- Stroke Trials Unit, Mental Health and Clinical Neuroscience (P.M.B.), University of Nottingham, United Kingdom.
- Department of Neuroscience and Experimental Therapeutics, Institute for Biomedical Research of Barcelona, Spanish National Research Council, and Institut D'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcel…
- Faculty of Biology, Medicine and Health, Division of Neuroscience, School of Biological Sciences, The University of Manchester, United Kingdom (S.M.A.).
- Geoffrey Jefferson Brain Research Centre, Manchester Academic Health Science Centre, United Kingdom (S.M.A.).
- School of Life Sciences, University of Warwick, Coventry, United Kingdom (J.B.).
ORCID-Profile: Cenk Ayata, Philip M Bath, Anna M Planas, Stuart M Allan, Johannes Boltze, Claire L Gibson, Marilyn J Cipolla, Marcio A Diniz, Stefano Fumagalli, Fahmeed Hyder, Raymond C Koehler, Arthur Liesz, Sarah K McCann, Louise D McCullough, Emily S Sena, Simone Beretta, Jaroslaw Aronowski, Francesca Bosetti, Clinton B Wright, Patrick D Lyden, Lauren H Sansing
Förderung
- NINDS NIH HHS
- NCI NIH HHS
- NIA NIH HHS
- NIMH NIH HHS
Zitieren
APA
Ayata, C., Bath, P. M., Planas, A. M., Allan, S. M., Boltze, J., Cabeen, R. P., Gibson, C. L., Cipolla, M. J., Diniz, M. A., Fumagalli, S., Hyder, F., Koehler, R. C., Liesz, A., McCann, S. K., Magnus, T., McCullough, L. D., Sena, E. S., Beretta, S., Aronowski, J., …, & Sansing, L. H. (2026). Preclinical Ischemic Stroke Multicenter Trials (PRISM) Collective Statement: Opportunities, Challenges, and Recommendations for a New Era. Stroke, 57(1). https://doi.org/10.1161/strokeaha.125.052056
Vancouver
Ayata C, Bath PM, Planas AM, Allan SM, Boltze J, Cabeen RP, et al. Preclinical Ischemic Stroke Multicenter Trials (PRISM) Collective Statement: Opportunities, Challenges, and Recommendations for a New Era. Stroke. 2026;57(1). doi:10.1161/strokeaha.125.052056
BibTeX
@article{Ayata2026,
author = {Ayata, Cenk and Bath, Philip M and Planas, Anna M and Allan, Stuart M and Boltze, Johannes and Cabeen, Ryan P and Gibson, Claire L and Cipolla, Marilyn J and Diniz, Marcio A and Fumagalli, Stefano and Hyder, Fahmeed and Koehler, Raymond C and Liesz, Arthur and McCann, Sarah K and Magnus, Tim and McCullough, Louise D and Sena, Emily S and Beretta, Simone and Aronowski, Jaroslaw and Bosetti, Francesca and Wright, Clinton B and Lyden, Patrick D and Sansing, Lauren H},
title = {Preclinical Ischemic Stroke Multicenter Trials (PRISM) Collective Statement: Opportunities, Challenges, and Recommendations for a New Era},
journal = {Stroke},
year = {2026},
volume = {57},
number = {1},
doi = {10.1161/strokeaha.125.052056}
}
EUVIMED